Markets

C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected

An image of a pen on a stock chart
Credit: Shutterstock photo

Murray Hill, NJ-based C.R. Bard Inc.BCR reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.

Net sales during the fourth quarter of 2016 increased from $870.8 million on a year-over-year basis to $967.1 million. The figure was also better than the Zacks Consensus Estimate of $956 million.

Stock Performance

Over the last three months, the stock gained 7.75% comparing favorably with the Zacks classified Medical/Dental Supplies sub industry's gain of 3.98%. Also, a long-term expected earnings growth rate of 11.17% instills confidence in investors.

C.R. Bard, Inc. Price, Consensus and EPS Surprise

C.R. Bard, Inc. Price, Consensus and EPS Surprise | C.R. Bard, Inc. Quote

Quarter Highlights

Net sales in the U.S. were $655.0 million and net sales outside the U.S. were $312.1 million, reflecting an increase of 8% and 18%, respectively, over the prior-year period.

Segment Details

Vascular product sales increased 9% year over year (up 10% at cc) to $262.0 million.

Coming to Urology, sales increased 16% on a year-over-year basis (up 18% at cc) to $253.0 million.

Oncology sales were up 9% (up 10% at cc) year over year to $259.4 million.

Surgical Specialties sales were up 9% (up 10% at cc) year over year to $167.2 million.

Sales from the 'other product line' increased 11% on a year-over-year basis to almost $25.5 million.

2017 Guidance

For full-year 2017, C.R. Bard projects net sales to increase between 4% and 5% on an as-reported basis. Excluding the impact of foreign exchange, net sales are projected to increase between 6% and 6.5% from the prior year. Earnings per share, after adjusting for amortization of intangibles, are projected between $11.45 and $11.75, representing growth of 11% to 14% year over year.

Zacks Rank & Key Picks

Currently, C.R. Bard carries a Zacks Rank #3 (Hold).

Better-ranked stocks in the broader medical sector include Addus Glaukos Corporation GKOS , Dextera Surgical Inc. DXTR and Hologic, Inc. HOLX . Notably, Addus Glaukos sports a Zacks Rank #1 (Strong Buy) while Dextera and Hologic have a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 161.3%.

Dextera Surgical has a long-term expected earnings growth rate of 25. Additionally, the company posted a promising one-month return of almost 57.1%.

Hologic has a long-term expected earnings growth rate of roughly 10.34%. Notably, the stock represents a solid one-year return of 21.47%.

The Best Place to Start Your Stock Search

Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Hologic, Inc. (HOLX): Free Stock Analysis Report

C.R. Bard, Inc. (BCR): Free Stock Analysis Report

Glaukos Corporation (GKOS): Free Stock Analysis Report

Dextera Surgical Inc. (DXTR): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GKOS HOLX

Other Topics

Earnings Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More